Yuchen Xia

Working Opportunity Fund (EVCC) Ltd seeks investment opportunities in companies located in British Columbia (Canada). The fund targets companies operating in the fields of information technology, life sciences, and clean technologies. It provides financing for early and later stage capital requirements.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Contextmedia Health LLC owns and operates a digital healthcare networks. It provides condition-specific programming and ad-supported content at point-of-care facilities. The firm also empowers healthcare professionals to engage patients while curating content personalized for each member office. The company was founded by Shradha Agarwal and Rishi U. Shah in 2006 and is headquartered in Chicago, IL.

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

Part of ConocoPhillips, Conoco Canada Ltd. is the Canadian division of ConocoPhillips, the world's largest independent exploration and production company based on production and proved reserves. ConocoPhillips explores for, develops, and produces crude oil and natural gas in Canada.

Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Ecotrust Canada is an organization that collaborates with rural, remote, and indigenous communities to create a sustainable economy that supports a healthy and resilient natural environment, as well as sustainable and abundant energy, food, and housing. The private company is based in Vancouver, Canada. The Canadian company also aims to promote prosperous and meaningful livelihoods, vibrant cultures, and inclusive societies. The company was founded in 1994 by Jacqueline L. Koerner, and the CEO is Chuck Rumsey.

Young Presidents' Organization, Inc. is a global leadership community of over 30,000 chief executives from 142 countries. The non-profit company is based in Irving, TX and has a global presence of subsidiaries in several regions. The company's mission is to help its members become better leaders and better people. The company was founded in 1950 by Ray Hickok, Khalid Mohamed Jassem Kanoo. Thayer Smith has been the CEO of the company since 2007.

Order of Canada is an organization based in Ottawa, Canada. The organization is affiliated with the governor general of Canada, La gouverneure générale du.

Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada.

The Michael Smith Foundation for Health Research operates as a health research funding agency. The non-profit company is based in Vancouver, Canada. Diane Finegood has been the CEO of the Canadian company since 2012.

Canadian Partnership Against Cancer initiates and implements cancer control programs. It offers prevention and screening; diagnosis and clinical care; person-centered perspective; research; system performance; knowledge management; and public engagement and outreach. The company is headquartered in Toronto, Canada.

viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada.

BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA.

Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist.

Institute for Health System Transformation & Sustainability operates to improve health care systems in British Columbia. Its projects include NeuroDevNet, emergency medicine network, and ministry projects. The company was founded in 2010 and is headquartered in Vancouver, Canada.

Part of Premier Diversified Holdings, Inc., Premier Diagnostic Center (Vancouver), Inc. engages in providing, designing and operating advanced nuclear medicine diagnostic imaging services. The company is based in Vancouver, Canada. The CEO of the Canadian company is Simon Sutcliffe.

Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada.

Terramera, Inc. manufactures pesticides and agrochemicals products. It offers biopesticides for the control of bed bugs and other household pests, biopesticides for agricultural use in a variety of crops and applications for bee health, cold pressed neem oil, neem cake, karanja oil, karanja cake, and other ecologically friendly products for use in agriculture, human health, and cosmetic applications; and other professional products. The company was founded by Karn Manhas and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018.

ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada.